Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids.

B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Health care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body ...

Earnings Call Insights: Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving ...

The company's primary asset is a hepatitis B vaccine called Heplisav-B that continues to gain market share in a growing market due to its 'best of breed' combination of efficacy and compliance ...

Its flagship product, Heplisav-B, is a hepatitis B vaccine for adults that offers full protection with a two-dose regimen, unlike traditional three-dose vaccines. The company uses its proprietary ...

In 2024, we delivered across our strategic priorities, including achieving record fourth quarter and annual HEPLISAV-B product revenue, advancing our pipeline programs, achieving profitability ...

The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant ...

Dynavax Technologies Corporation (NASDAQ:DVAX) continues to solidify its position in the hepatitis B vaccine market with its flagship product HEPLISAV-B. The company's focus on leveraging this ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected ...